Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05305287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quantifying Hepatic Mitochondrial Fluxes in Humans

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints reordered
    • Eligibility criteria expanded, about 2 words
    v7
  2. 2 versions Re-verified since Aug 29, 2024, no change to tracked fieldsv5-v6
  3. Primary endpoints: 2 to 1
    • Secondary endpoints expanded, about 80 words
    • Study description expanded, about 18 words
    v4
  4. Primary completion date: Feb 1, 2026 to Mar 31, 2027
    • Start date: Feb 1, 2022 to Nov 1, 2022
    • Study completion date: Feb 1, 2027 to Mar 31, 2027
    • Eligibility criteria revised
    v3
  5. Collaborators expanded, about 10 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Trial Details
NCT Number NCT05305287
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Related terms Diabetes Mellitus, Type 2, Insulin Resistance, Non-alcoholic Fatty Liver Disease
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov